Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer

Leucoselect Phytosome 用于早期肺癌新辅助治疗

基本信息

  • 批准号:
    10316152
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-10-01 至 2025-09-30
  • 项目状态:
    未结题

项目摘要

Ample preclinical data suggests that grape seed procyanidin extract (GSE) possesses multi-faceted anticancer properties. GSE has been shown to favorably modulate carcinogenic mechanisms, including 1) major eicosanoids pathways, such as inhibitions of cyclocoxygenase (COX)-2/prostaglandin (PG)E2, induction of prostacyclin synthase (PTGIS)/PGI2 and increase production of 15(S)-hydroxy-eicosatetraenoic acid (15-HETE); 2) downregulation of oncomirs microRNA (miR)-19a, -19b and up-regulations of their downstream targets - tumor suppressors insulin-like growth factor II receptor (IGF-2R) and phosphatase and tensin homolog (PTEN), resulting in reduction of phosphorylated (P)-AKT, as well as downregulation of oncomir miR-106b and upregulation of its target – the tumor suppressor P21. Recently, we have found that oral leucoselect phytosome (LP), a standardized GSE complexed with soy phospholipid to enhance bioavailability, significantly inhibited human lung cancer xenograft growth, reduced bronchial Ki-67 labeling index (a marker of proliferation), favorably modulated major eicosanoids pathways, and downregulated serum miR-19a, -19b, and -106b in heavy current/former smokers. We therefore hypothesize that oral administration of LP is safe, can favorably modulate mechanisms associated with lung cancerization, and be useful for lung cancer treatment. To test these hypotheses, a single arm, phase IIa neoadjuvant lung cancer treatment study using LP, will be conducted in 30 patients with newly diagnosed, stage I and II resectable lung cancer. Aim #1: will determine the safety, feasibility and pharmacokinetics (PK)/pharmacodynamics (PD) of 2-3 weeks of oral LP in stage I or II nonsmall cell lung cancer (NSCLC) patients prior to resection. Subjects will consent to study participation and archive of specimens for research, including blood, urine, and from diagnostic procedures, such as bronchoscopy [bronchoalveolar lavage (BAL) fluid and cells, lesion biopsies and lymph node (LN) sampling] and/or transthoracic needle aspiration (TTNA) as clinically indicated, to be used as pre- treatment samples. Qualified subjects who are diagnosed with resectable lung cancer will be enrolled and treated for ~2-3 weeks until surgical resection. At the time of surgery, serial clinical specimens, including BAL, LN, lung tumor/adjacent tissue, blood and urine will be collected as post-treatment samples for assessing PK/bioavailability, PD and mechanism of actions when applicable. The safety of oral LP will be monitored weekly with the NCI common terminology criteria for adverse events Version 5.0 and adverse reaction questionnaires. Aim #2: To determine the antineoplastic and mechanistic effects of oral LP in stage I/ II lung cancer patients. The anticancer effects of LP will be assessed by comparing its bioactivity pre- vs. post-treatment, as measured by modulations of tumor pathological response, downstaging, Ki-67 labeling index, activated caspase 3 (apoptosis marker), COX-2, PTGIS, 15-LOX, PTEN, P-AKT, IGF2R; 2) markers of inflammation and antitumor immunity: PGE2, PGI2, 15-HETE, interleukin (IL)-6, -10, -12, C reactive protein (CRP) In BAL, plasma, and/or tumors; 3) cancer-relevant, pathway specific gene expression profile in BAL cells and tumors; 4) epigenetic miRNA profile in BAL cells and tumors; 5) miR-19a, -19b, and -106b in serum and tumors. Aim #3: will validate the roles of miR-19a, miR-19b, and miR-106b in mediating the anti-neoplastic effects of GSE and the utility of serum miR-19a, -19b, and -106b as surrogate endpoint biomarkers (SEBM) for therapeutic monitoring. In our previous studies, we found that GSE significantly down-regulated well-known lung cancer oncomirs miR-19a, -19b, and -106b in human lung neoplastic cells and A549 xenograft tumors in nude mice, as well as in the serum of heavy current/former smokers. Findings will provide important insights into the feasibility and mechanistic effects of GSE/LP against lung cancer, help identify SEBM and set the stage for future confirmatory clinical trials.
大量临床前数据表明,葡萄籽原花青素提取物(GSE)具有多方面的抗癌作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JENNY T MAO其他文献

JENNY T MAO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JENNY T MAO', 18)}}的其他基金

Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Leucoselect Phytosome 用于早期肺癌新辅助治疗
  • 批准号:
    10013949
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Leucoselect Phytosome 用于早期肺癌新辅助治疗
  • 批准号:
    10729099
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Leucoselect Phytosome 用于早期肺癌新辅助治疗
  • 批准号:
    10578652
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Combinations of Grape Seed and Milk Thistle Extracts Against Lung
葡萄籽和水飞蓟提取物的组合对肺的作用
  • 批准号:
    10663805
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Combinations of Grape Seed and Milk Thistle Extracts Against Lung
葡萄籽和水飞蓟提取物的组合对肺的作用
  • 批准号:
    10046283
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Combinations of Grape Seed and Milk Thistle Extracts Against Lung
葡萄籽和水飞蓟提取物的组合对肺的作用
  • 批准号:
    9562906
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Combinations of Grape Seed and Milk Thistle Extracts Against Lung
葡萄籽和水飞蓟提取物的组合对肺的作用
  • 批准号:
    10421238
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Feasibility of grape seed extract for lung cancer chemoprevention
葡萄籽提取物用于肺癌化学预防的可行性
  • 批准号:
    8926891
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Feasibility of grape seed extract for lung cancer chemoprevention
葡萄籽提取物用于肺癌化学预防的可行性
  • 批准号:
    8735100
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Feasibility of grape seed extract for lung cancer chemoprevention
葡萄籽提取物用于肺癌化学预防的可行性
  • 批准号:
    8583907
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:

相似海外基金

A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
  • 批准号:
    MR/X00094X/1
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
  • 批准号:
    22K06738
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
  • 批准号:
    22K15910
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
  • 批准号:
    19K17779
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
  • 批准号:
    18K00267
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
  • 批准号:
    379425
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
  • 批准号:
    9576448
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
  • 批准号:
    16K15156
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
  • 批准号:
    367156
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了